Literature DB >> 2720727

Enhancement of cytocidal and antitumor effect of cisplatin by caffeine in human osteosarcoma.

K Tomita1, H Tsuchiya.   

Abstract

A nontoxic dose of caffeine enhanced the cytotoxicity of cisplatin in human osteosarcoma cells (OST strain). Synergistic cytotoxicity was seen in vitro in OST cells when 2 mmol caffeine was added to a nontoxic dose of cisplatin (2 micrograms/ml). Caffeine reduced S-phase, G2/M-phase, and S-and-G2/M-phase accumulation by cisplatin on the DNA histogram, and nuclear fragmentation of tumor cells was frequently observed. Flow cytometric analysis appeared to be useful in assessing the efficacy of the combination of cisplatin and caffeine. The antitumor effect of the combination of cisplatin and caffeine was examined in OST transplanted to BALB/C athymic mice. Regression of the tumor was observed when cisplatin was given at a dose of 10 mg/kg. When 4 mg of caffeine was given once a day for three days after the administration of cisplatin, marked regression of the tumor was observed in groups treated with 5 or 10 mg/kg of cisplatin, without significant weight loss. These results indicate that caffeine enhances the antitumor effect of cisplatin on transplanted osteosarcoma in BALB/C athymic mice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720727

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

1.  Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases.

Authors:  Michiaki Karita; Hiroyuki Tsuchiya; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Hideji Nishida
Journal:  Int J Clin Oncol       Date:  2011-11-01       Impact factor: 3.402

2.  Effect of chemotherapy combined with caffeine for osteosarcoma.

Authors:  H Tsuchiya; H Yasutake; A Yokogawa; H Baba; Y Ueda; K Tomita
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin.

Authors:  Y Sadzuka; A Iwazaki; T Sugiyama; T Sawanishi; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1998-02

4.  Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity.

Authors:  Y Sadzuka; A Iwazaki; A Miyagishima; Y Nozawa; S Hirota
Journal:  Jpn J Cancer Res       Date:  1995-06

5.  Caffeine modulates the antitumor activity and toxic side effects of adriamycin.

Authors:  Y Sadzuka; E Mochizuki; Y Takino
Journal:  Jpn J Cancer Res       Date:  1993-03

6.  Methylxanthines: Potential Therapeutic Agents for Glioblastoma.

Authors:  Daniel Pérez-Pérez; Iannel Reyes-Vidal; Elda Georgina Chávez-Cortez; Julio Sotelo; Roxana Magaña-Maldonado
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.